Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

the completion of the Phase 1 clinical trials for AT2220 for the treatment of Pompe disease, the start of Phase 2 studies for AT2220 and the possibility and timing of conducting clinical trials of AT2220 and ERT combination therapy; (ii) statements regarding the timing and goals of discussions with US and EU regulatory authorities on the Phase 3 study and regulatory pathway for Amigal; (iii) statements on the goals, progress and timing of preclinical studies in Parkinson's disease and other research efforts aimed at evaluating disease targets in neurodegenerative and metabolic disorders; (iv) statements on the range of "cash burn" for Amicus in 2008, the need to raise additional capital in 2008 and the trends for incurring research and development expense in 2008; and (v) statements regarding expected milestone and research reimbursement payments from Shire. These forward looking statements are based on the current estimates and assumptions of the management of Amicus as of the date of this press release and the conference call and are subject to risks, changes in circumstances, assumptions and uncertainties and other factors that may cause the actual results of Amicus to be materially different from those reflected in the forward looking statements. Important factors that may cause actual results to differ materially from those indicated by forward looking statements include, among others, the potential that results of clinical or preclinical studies indicate that product candidates are unsafe or ineffective, our dependence on third parties in the conduct of our clinical studies, delays or failure to achieve regulatory approvals, risks of relying on third party manufacturers for the supply of our product candidates, we or our licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of our product candidates and risks of collaborating with third parties to develop and commercialize products. Th
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 /PRNewswire-iReach/ -- A case study ... between the school,s bioengineering department and the Intel® ... Intel® Software Academic Program, UCSD,s research focuses on ... human body.  Photo - ... the work of Dr. Todd P. Coleman ...
(Date:8/19/2014)... Piscataway, NJ (PRWEB) August 20, 2014 ... engineering and regenerative medicine is an inadequate vascular ... engineered constructs and decellularized tissues is critical for ... Researchers have attempted to mitigate deficiencies in vascularization ... including adding scaffold bioactivity, optimizing scaffold design and ...
(Date:8/19/2014)... 2014 Cellgen Diagnostics ... to fund a corporate lab for its genetic-based ... development is a critical component in the move ... the implementation of personalized medicine – a more ... , Indiegogo contributions will support Cellgen’s intent to ...
(Date:8/19/2014)... , Aug. 19, 2014 ... addition of the "Spectroscopy Equipment and ... report to their offering. ... Spectroscopy Equipment and Accessories in US$ Thousands ... (UV-Vis spectrophotometers, Raman Spectrometers, NMR-EPR Spectrometers, Near ...
Breaking Biology Technology:Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2
... 13, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
... sunscreens when they are exposed to sunlight? And how is ... has been the subject of research at the University of ... at the upcoming dermatologist conference in Gothenburg. A growing ... habits have brought an increase in the number of cases ...
... Beta-Pro LLC, announced today that it has ... pharmaceutical drug discovery and research institutes in the ... company now manages extensive laboratory facilities in the ...   "Beta-Pro has already established a ...
Cached Biology Technology:Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 2Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 3Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 4Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 5Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 6Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 7Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 8Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 9So that's why we're allergic to sun creams 2Beta-Pro Expands Operations to Meet Demands for Human Cells in Hepatocyte Drug Discovery Market 2
(Date:8/20/2014)... salty aroma of sunscreen and seawater signals a relaxing ... that the idyllic beach vacation comes with an environmental ... into the sea, they can become toxic to some ... course for many other marine animals. Their study appears ... . , Antonio Tovar-Sanchez and David Snchez-Quiles point out ...
(Date:8/20/2014)... A new gene therapy developed by researchers at the ... to protect mice from a life-threatening heart condition caused ... therapeutic avenue," said Yi Lai, Ph.D., the leading author ... MU School of Medicine,s Department of Molecular Microbiology and ... hope this could lead to a treatment for people ...
(Date:8/20/2014)... DENVER , Aug. 20, 2014  The ... take place in Tampa, Florida ... interactive sessions with Steven Rahman, Director, Technology and Strategy ... Sector at Experian. The theme of this year,s ... and Privacy. "Biometrics UnPlugged: Mobility ...
Breaking Biology News(10 mins):Gene therapy protects mice from lethal heart condition, MU researchers find 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2
... Athens, Ga. For more than a century, the ... it comes to human health. As it turns out, X-rays ... and a new approach -- just published by researchers at ... can learn using the technique. One of the primary ...
... a recent study by the University of Santiago de Compostela ... unexpected increase in hydrocarbon levels along the coast of Galicia ... years by works to remove the wreck, pollution levels began ... numerous forest fires., On 19th November 2002 the oil tanker ...
... only become a science in the past 25 years, ... with widespread international collaboration, broad disciplinary composition and wide ... National Laboratory and Indiana University. The findings, published today ... Sciences, were assembled from a review of 20,000 ...
Cached Biology News:New strategy could lead to dose reduction in X-ray imaging 2New strategy could lead to dose reduction in X-ray imaging 3Hydrocarbon pollution along the coast of Galicia shot up five years after the Prestige oil spill 2After 25 years, sustainability is a growing science that's here to stay 2
... At the forefront of Agilent analytical ... Built-in local area networking (LAN) allows you ... sites--for fast and informed decision making. Just ... has all the flexibility and performance needed ...
... Inc.'s CP-4900 is a rugged, ... delivers the information you need ... the composition of gas mixtures ... micro-Gas Chromatograph generates more data ...
... GC system combines world-class performance hardware, Cerity ... Agilents world-renowned support and columns, as well ... combination that lets you reach uncompromising results ... dependable data. The Agilent 6820 GC system ...
... Peroxisome Proliferator-Activated Receptor-gamma (PPARGamma) Competitor ... and efficient method for studying ... using fluorescence polarization (FP). The ... domain (PPARGamma-LBD) with an N-terminal ...
Biology Products: